|
| Home : Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review |
|
Feb 11
2020 |
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review |
|
EAST HANOVER, N.J., Feb. 11, 2020 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib's (INC280) New Drug Application (NDA). Capmatinib is a MET inhibitor being evaluated as a treatment for first-line... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/novartis-announces-met-inhibitor-capmatinib-inc280-the-first-potential-treatment-for-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review-301002504.html |
| |
|
Related News
|
» Aker BP ASA: Fourth Quarter 2019 Results and Capital Markets Update
» Pentagon: 109 troops suffer brain injuries from Iran strike
|
|
|
